Quest Diagnostics Incorporated: shareholders and insiders

DGXNYSEHealthcare · Services-Medical Laboratories

Price

$259.69

November 18, 2026Market cap $28.5B

What Ploutos Investor adds for Quest Diagnostics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Nov 16, 2026, from their own Form 4 filings.

29 Form 4s

Bought on the market

–

nobody

Sold on the market

$47M

9 people

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan98%
  • The rest2%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $37M by 8 people

  • 2025: no buys, sold $11M by 2 people
  • 2026: no buys, sold $37M by 8 people
  • Nov 13, 2026Michael J DeppeSVP, Corp. Controller & CAO
    Kind10b5-1
  • Nov 13, 2026Michael J DeppeSVP, Corp. Controller & CAO
    Kind10b5-1
  • Nov 13, 2026Michael J DeppeSVP, Corp. Controller & CAO
    Kind10b5-1
  • Nov 13, 2026Michael J DeppeSVP, Corp. Controller & CAO
    Kind10b5-1
  • Nov 9, 2026Patrick PlewmanSVP for Diagnostic Services
    Kind10b5-1
  • Nov 9, 2026Patrick PlewmanSVP for Diagnostic Services
    Kind10b5-1
  • Nov 9, 2026Patrick PlewmanSVP for Diagnostic Services
    Kind10b5-1
  • Nov 9, 2026Patrick PlewmanSVP for Diagnostic Services
    Kind10b5-1
  • Nov 9, 2026Patrick PlewmanSVP for Diagnostic Services
    Kind10b5-1
  • Nov 3, 2026Subu RamachandranSVP, Regional Businesses
    Kind
  • Nov 3, 2026Catherine T. DohertyExecutive Vice President
    Kind10b5-1
  • Nov 3, 2026Catherine T. DohertyExecutive Vice President
    Kind10b5-1
  • Nov 3, 2026Catherine T. DohertyExecutive Vice President
    Kind10b5-1
  • Nov 3, 2026Catherine T. DohertyExecutive Vice President
    Kind10b5-1
  • Nov 3, 2026Catherine T. DohertyExecutive Vice President
    Kind10b5-1
  • Nov 3, 2026Catherine T. DohertyExecutive Vice President
    Kind10b5-1
  • Nov 3, 2026Catherine T. DohertyExecutive Vice President
    Kind10b5-1
  • Nov 3, 2026Catherine T. DohertyExecutive Vice President
    Kind10b5-1
  • Nov 3, 2026Catherine T. DohertyExecutive Vice President
    Kind10b5-1
  • Nov 3, 2026Mark E DelaneySVP & Chief Commercial Officer
    Kind
  • Oct 26, 2026Gary M PfeifferDirector
    Kind10b5-1
  • Oct 21, 2026Robert B CarterDirector
    Kind
  • Oct 21, 2026Sam SamadExecutive Vice President & CFO
    Kind
  • Oct 21, 2026Vicky B GreggDirector
    Kind
  • Oct 21, 2026Karthik KuppusamySVP, Clinical Solutions
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by DGX's officers and directors from 2006 up to November 18, 2025, 20 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

4 Holders over 5%Nov 10, 2026 Latest filing
  • BlackRock, Inc.
    Share of class8.40%
  • Vanguard Capital Management
    Share of class7.53%
  • Vanguard Portfolio Management
    Share of class5.54%
  • State Street
    Share of class5.00%
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • T. Rowe Price Associates, Inc.4.90%Aug 14, 202613G/A
  • The Vanguard Group0.00%Mar 27, 202613G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Citadel Advisors (Griffin)
    In the quarter+224%
  • Millennium Mgmt (Englander)
    In the quarter×10.3
  • Point72 (Cohen)
    In the quarter
  • Bridgewater (Dalio)
    In the quarter-5.5%
  • D.E. Shaw
    In the quarter+261%
  • AQR Capital
    In the quarter+11%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 3.25% of its shares outstanding were held short, +4.6% since the report before.

Shares held short
3.57M
3.25%
Since the report before3.42M on Sep 30, 2026
+4.6%
3.4
1.06M
More days to cover thanof 4,578 US-listed companies with enough volume
40%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 2.51M
  • Nov 15, 2023: Shares held short 2.69M
  • Nov 30, 2023: Shares held short 2.27M
  • Dec 15, 2023: Shares held short 2.55M
  • Dec 29, 2023: Shares held short 2.49M
  • Jan 12, 2024: Shares held short 3.04M
  • Jan 31, 2024: Shares held short 3.44M
  • Feb 15, 2024: Shares held short 2.97M
  • Feb 29, 2024: Shares held short 2.75M
  • Mar 15, 2024: Shares held short 2.65M
  • Mar 28, 2024: Shares held short 2.55M
  • Apr 15, 2024: Shares held short 3.02M
  • Apr 30, 2024: Shares held short 2.80M
  • May 15, 2024: Shares held short 2.70M
  • May 31, 2024: Shares held short 2.65M
  • Jun 14, 2024: Shares held short 2.36M
  • Jun 28, 2024: Shares held short 2.27M
  • Jul 15, 2024: Shares held short 2.28M
  • Jul 31, 2024: Shares held short 2.33M
  • Aug 15, 2024: Shares held short 2.79M
  • Aug 30, 2024: Shares held short 2.55M
  • Sep 13, 2024: Shares held short 2.42M
  • Sep 30, 2024: Shares held short 1.97M
  • Oct 15, 2024: Shares held short 2.33M
  • Oct 31, 2024: Shares held short 2.38M
  • Nov 15, 2024: Shares held short 2.59M
  • Nov 29, 2024: Shares held short 2.04M
  • Dec 13, 2024: Shares held short 1.91M
  • Dec 31, 2024: Shares held short 2.03M
  • Jan 15, 2025: Shares held short 2.27M
  • Jan 31, 2025: Shares held short 2.58M
  • Feb 14, 2025: Shares held short 2.96M
  • Feb 28, 2025: Shares held short 2.57M
  • Mar 14, 2025: Shares held short 2.76M
  • Mar 31, 2025: Shares held short 2.86M
  • Apr 15, 2025: Shares held short 3.50M
  • Apr 30, 2025: Shares held short 4.01M
  • May 15, 2025: Shares held short 3.90M
  • May 30, 2025: Shares held short 3.82M
  • Jun 13, 2025: Shares held short 3.64M
  • Jun 30, 2025: Shares held short 4.98M
  • Jul 15, 2025: Shares held short 4.58M
  • Jul 31, 2025: Shares held short 4.74M
  • Aug 15, 2025: Shares held short 4.03M
  • Aug 29, 2025: Shares held short 4.25M
  • Sep 15, 2025: Shares held short 4.42M
  • Sep 30, 2025: Shares held short 4.33M
  • Oct 15, 2025: Shares held short 3.95M
  • Oct 31, 2025: Shares held short 4.61M
  • Nov 14, 2025: Shares held short 4.29M
  • Nov 28, 2025: Shares held short 4.30M
  • Dec 15, 2025: Shares held short 4.23M
  • Dec 31, 2025: Shares held short 5.85M
  • Jan 15, 2026: Shares held short 5.72M
  • Jan 30, 2026: Shares held short 5.82M
  • Feb 13, 2026: Shares held short 4.77M
  • Feb 27, 2026: Shares held short 3.87M
  • Mar 13, 2026: Shares held short 3.87M
  • Mar 31, 2026: Shares held short 4.17M
  • Apr 15, 2026: Shares held short 3.55M
  • Apr 30, 2026: Shares held short 3.39M
  • May 15, 2026: Shares held short 3.72M
  • May 29, 2026: Shares held short 3.43M
  • Jun 15, 2026: Shares held short 3.42M
  • Jun 30, 2026: Shares held short 3.73M
  • Jul 15, 2026: Shares held short 3.51M
  • Jul 31, 2026: Shares held short 3.68M
  • Aug 14, 2026: Shares held short 3.32M
  • Aug 31, 2026: Shares held short 3.45M
  • Sep 15, 2026: Shares held short 3.60M
  • Sep 30, 2026: Shares held short 3.42M
  • Oct 15, 2026: Shares held short 3.57M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading64.4% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 64.4% of the shares in the reported trades were short sales, against 55.5% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
64.4%
The 14 beforeOct 12, 2026 – Oct 29, 2026
55.5%
Change
+8.9 pts
Short sales a dayon average, of 344.2K shares
221.6K
More than atof 3,656 US-listed companies, same days
91%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 28.7%
  • Oct 13, 2026: Short sales 32.5%
  • Oct 14, 2026: Short sales 33.9%
  • Oct 15, 2026: Short sales 34.5%
  • Oct 16, 2026: Short sales 49.3%
  • Oct 19, 2026: Short sales 52.3%
  • Oct 20, 2026: Short sales 42%
  • Oct 21, 2026: Short sales 73.1%
  • Oct 22, 2026: Short sales 63.4%
  • Oct 23, 2026: Short sales 75.5%
  • Oct 26, 2026: Short sales 74.9%
  • Oct 27, 2026: Short sales 73.1%
  • Oct 28, 2026: Short sales 66%
  • Oct 29, 2026: Short sales 72.7%
  • Oct 30, 2026: Short sales 82.5%
  • Nov 2, 2026: Short sales 78.2%
  • Nov 3, 2026: Short sales 72.5%
  • Nov 4, 2026: Short sales 55.1%
  • Nov 5, 2026: Short sales 70.1%
  • Nov 6, 2026: Short sales 77.2%
  • Nov 9, 2026: Short sales 64.7%
  • Nov 10, 2026: Short sales 63.1%
  • Nov 11, 2026: Short sales 60.6%
  • Nov 12, 2026: Short sales 57.8%
  • Nov 13, 2026: Short sales 58.3%
  • Nov 16, 2026: Short sales 66.2%
  • Nov 17, 2026: Short sales 43%
  • Nov 18, 2026: Short sales 49%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

448.7K Insiders' shares0.41% Of the company
  • J. E. DavisCEO and President
    Directly122.4K
  • Catherine T. DohertyEVP, Regional Businesses
    Directly76.5K
  • Michael E PrevoznikSVP & General Counsel
    Directly44.2K
  • Michael J DeppeSVP, Corp. Controller & CAO
    Directly35.9K
  • Sam SamadExecutive Vice President & CFO
    Directly33.6K
  • Gary M PfeifferDirector
    Directly29.8K
  • Timothy L MainDirector
    Directly27.5K
  • Vicky B GreggDirector
    Directly18.4K
  • Karthik KuppusamySVP, Clinical Solutions
    Directly15.7K
  • Patrick PlewmanSVP for Diagnostic Services
    Directly14.7K
  • Mark E DelaneySVP & Chief Commercial Officer
    Directly13.0K
  • Wright Lassiter IIIDirector
    Directly10.3K
  • Robert B CarterDirector
    Directly3,874
  • Subu RamachandranSVP, Regional Businesses
    Directly2,832

A lower bound: it counts only the 14 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

10b5-1 trading plans

Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.

9 Adopted in the last 12 months15 Filings read
  • Karthik KuppusamySVP, Clinical Solutions
    What happenedAdoptedAug 26, 2026
    Shares1,000
  • Michael J. DeppeSVP, Corporate Controller and Chief Accounting Officer
    What happenedAdoptedAug 13, 2026
    Shares11.8K
  • Patrick PlewmanSVP, Diagnostic Services
    What happenedAdoptedAug 11, 2026
    Shares40.6K
  • James E. DavisChairman, Chief Executive Officer and President
    What happenedAdoptedAug 10, 2026
    Shares172.1K
  • Cathy DohertyEVP
    What happenedAdoptedAug 3, 2026
    Shares34.3K
  • Gary PfeifferDirector
    What happenedAdoptedMay 29, 2026
    Shares1,203
  • Mike PrevoznikSVP, General Counsel
    What happenedAdoptedMay 29, 2026
    Shares32.0K
  • Mark DelaneySVP, Chief Commercial Officer
    What happenedAdoptedApr 23, 2026
    Shares1,600
  • Karthik KuppusamySVP, Clinical Solutions
    What happenedAdoptedFeb 26, 2026
    Shares8,147
  • Cathy DohertyEVP, Regional Businesses
    What happenedAdoptedNov 14, 2025
    Shares37.4K

As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.

Executive pay

From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.

2025 Latest year6 Years on record

$15M

Actually paid: $27M

$3.3M

Actually paid: $5.2M

$161

Peers: $148

Adjusted Diluted Earnings Per Share

From the proxy statement (DEF 14A) of Apr 6, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A

Share repurchases

How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.

$879M Repurchases over 4 quarters$436M Left in the program
  • Dec 31, 202510-K
    Amount$302M
  • Sep 30, 202510-Q
    Amount$151M
  • Dec 31, 202410-K
    Amount$150M
  • Dec 31, 202310-K
    Amount$276M
  • Dec 31, 202210-K
    Amount$435M
  • Sep 30, 202210-Q
    Amount$400M
  • Jun 30, 202210-Q
    Amount$200M
  • Mar 31, 202210-Q
    Amount$378M

From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 12 filing(s) not shown, as the table was not read or did not agree with the cash.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

50 ETFs holding it3.50% The largest weight (IHF)
  • IHFiShares U.S. Healthcare Providers ETF
    Weight in the fund3.50%
  • QLTYGMO U.S. Quality ETF
    Weight in the fund1.01%
  • SPLVInvesco S&P 500 Low Volatility ETF
    Weight in the fund0.86%
  • COWZPacer US Cash Cows 100 ETF
    Weight in the fund0.46%
  • FVDFirst Trust Value Line Dividend Index Fund
    Weight in the fund0.43%
  • IYHiShares U.S. Healthcare ETF
    Weight in the fund0.42%
  • XLVState Street(R) Health Care Select Sector SPDR(R) ETF
    Weight in the fund0.41%
  • VOEVanguard Mid-Cap Value Index Fund
    Weight in the fund0.40%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.37%
  • IXJiShares Global Healthcare ETF
    Weight in the fund0.30%

50 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

1,107 Managers, Q2 2026$22.2B Value of their positions
  • Q3 2025: Managers 1,008
  • Q4 2025: Managers 1,050
  • Q1 2026: Managers 1,074
  • Q2 2026: Managers 1,107

Institutional investors by quarter

The fund managers holding DGX, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 1,107 managers held 105M shares, worth $22.2B. During the quarter 117 opened a position, 84 closed one, 420 added and 349 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+1.1%
  • Vanguard Capital Management
    In the quarter+1.2%
  • Vanguard Portfolio Management
    In the quarter+0.8%
  • State Street
    In the quarter+2.5%
  • Price T Rowe Associates
    In the quarter-14%
  • Boston Partners
    In the quarter+18%
  • JPMorgan Chase
    In the quarter-8.5%
  • Geode Capital Management
    In the quarter+1.7%
  • Morgan Stanley
    In the quarter-0.8%
  • EdgePoint Investment Group
    In the quarter+0.2%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

The full analysis

What do Quest Diagnostics's filings show?

Who buys and sells is one part of Quest Diagnostics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about DGX's shareholders

Didn't find what you were looking for?

Ask us
Have DGX's insiders bought or sold?

From Jun 2, 2026 to Nov 16, 2026 Quest Diagnostics's insiders bought 0 and sold $24M of shares on the market. 100% of the sales were under set 10b5-1 plans.

Which well-known managers hold DGX?

6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $101M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.